TY  - CHAP
M1  - Book, Section
TI  - Pulmonary Infection in Immunocompromised Hosts
A1  - Fishman, Jay A.
A2  - Grippi, Michael A.
A2  - Elias, Jack A.
A2  - Fishman, Jay A.
A2  - Kotloff, Robert M.
A2  - Pack, Allan I.
A2  - Senior, Robert M.
A2  - Siegel, Mark D.
PY  - 2015
T2  - Fishman's Pulmonary Diseases and Disorders, 5e
AB  - A  growing  group  of  individuals  who  have  acquired  immunodeficiency  syndrome  (AIDS),  who  are  receiving  immunosuppression  for  solid-organ  transplantation,  bone  marrow  transplantation  (BMT),  or  for  autoimmune  (“connective  tissue”  diseases),  who  have  primary  immune  deficiencies,  or  who  have  been  treated  with  chemotherapeutic  regimens  for  cancer,  have  increased  susceptibility  to  infection  as  a  result  of  acquired  or  intrinsic  immune  deficiencies.  Prolonged  survival  of  such  immunocompromised  individuals  reflects  the  deployment  of  newer  laboratory  assays  and  newer  antimicrobial  agents,  including  antifungal,  antibacterial,  and  antiviral  agents  (e.g.,  ganciclovir,  foscarnet,  oral  agents)  and  highly  active  antiretroviral  therapies  (HAART)  for  HIV  infection,  hematopoietic  growth  factors,  and  clinical  experience  in  caring  for  such  patients.  Wide  use  of  immunosuppressive  drugs,  including  “biologic  agents,”  which  are  generally  antibodies  targeting  specific  cell  types  or  pathways  of  inflammation,  has  further  expanded  susceptible  populations.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1122368760
ER  -